We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.61%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$870M
AUM Growth
-$103M
Cap. Flow
-$99.3M
Cap. Flow %
-11.41%
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$31.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$18.9M
3
DXCM icon
DexCom
DXCM
+$12.6M
4
COO icon
Cooper Companies
COO
+$10.8M
5
ELV icon
Elevance Health
ELV
+$10.4M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$24.2M
2
MRK icon
Merck
MRK
+$22.8M
3
CI icon
Cigna
CI
+$15.1M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$14.7M
5
BSX icon
Boston Scientific
BSX
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIR icon
76
Vir Biotechnology
VIR
$1.5B
$1.3M 0.15%
+200,000
New +$1.78M
ALKS icon
77
Alkermes
ALKS
$8.28B
$1.29M 0.15%
39,000
-38,999
-50% -$1.27M
KURA icon
78
Kura Oncology
KURA
$875M
$1.29M 0.15%
195,000
-119,526
-38% -$931K
ARVN icon
79
Arvinas
ARVN
$586M
$1.28M 0.15%
183,000
+27,500
+18% +$431K
AMGN icon
80
Amgen
AMGN
$224B
$1.25M 0.14%
4,000
+1,000
+33% +$295K
GERN icon
81
Geron
GERN
$1.03B
$1.24M 0.14%
783,000
-217,000
-22% -$528K
ICLR icon
82
Icon
ICLR
$12.9B
$1.22M 0.14%
+7,000
New +$1.36M
GPCR icon
83
Structure Therapeutics
GPCR
$3.71B
$1.21M 0.14%
+70,000
New +$1.71M
RLAY icon
84
Relay Therapeutics
RLAY
$4.37B
$1.21M 0.14%
460,000
– –
XENE icon
85
Xenon Pharmaceuticals
XENE
$6.09B
$1.17M 0.14%
35,000
– –
MEDP icon
86
Medpace
MEDP
$16.9B
$1.16M 0.13%
3,800
-3,000
-44% -$1.01M
ANNX icon
87
Annexon
ANNX
$870M
$888K 0.1%
460,000
-82,500
-15% -$275K
IMCR icon
88
Immunocore
IMCR
$1.74B
$839K 0.1%
28,278
-30,000
-51% -$900K
AVTR icon
89
Avantor
AVTR
$9.29B
$775K 0.09%
47,826
-14,000
-23% -$265K
IDYA icon
90
IDEAYA Biosciences
IDYA
$3.57B
$647K 0.07%
39,500
-42,500
-52% -$905K
APLS
91
DELISTED
Apellis Pharmaceuticals
APLS
$618K 0.07%
28,250
-167,341
-86% -$4.62M
PEN icon
92
Penumbra
PEN
$12.9B
$588K 0.07%
+2,200
New +$595K
RGEN icon
93
Repligen
RGEN
$9.43B
$573K 0.07%
4,500
-4,500
-50% -$693K
IMVT icon
94
Immunovant
IMVT
$8.35B
$443K 0.05%
25,924
-119,076
-82% -$2.49M
ACHC icon
95
Acadia Healthcare
ACHC
$2.89B
– –
-13,750
Closed -$545K
CRL icon
96
Charles River Laboratories
CRL
$13.4B
– –
-14,850
Closed -$2.74M
IGMS
97
DELISTED
IGM Biosciences
IGMS
– –
-126,064
Closed -$770K
NVO
98
Novo Nordisk
NVO
$208B
– –
-50,000
Closed -$4.3M
PLRX icon
99
Pliant Therapeutics
PLRX
$64.4M
– –
-116,250
Closed -$1.53M
SYK icon
100
Stryker
SYK
$133B
– –
-22,500
Closed -$8.1M
1 2 3
4
5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rhenman & Partners Asset Management held 104 positions worth $870M, down 11% from $973M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $99.3M in Q1 2025, closing 10 positions and reducing 55 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Bristol-Myers Squibb worth $19.8M.

  • Rhenman & Partners Asset Management's largest Q1 2025 buy was Bristol-Myers Squibb: 325,000 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Glaukos in Q1 2025, an estimated $31.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2025 reduction was Inspire Medical Systems, cutting an estimated $24.2M.
  • Rhenman & Partners Asset Management fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $14.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $870M portfolio in Q1 2025.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 10 in Q1 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 11% quarter-over-quarter to $870M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2025, filed 14 May 2025.